Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) and Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) have established Teva Takeda Yakuhin Ltd. Teva will have a 51% stake in the company and Takeda will own 49%.
As a result of this strategic move, Takeda, an R&D driven pharmaceutical company which has a long history as a leading company in Japan, and Teva, among the top 10 pharmaceutical companies in the world and the global leader in generics, will meet the wide-ranging needs of patients and growing importance of generics in Japan through the provision of off-patent drugs (products whose patents have expired).
As a result of the transfer of intangible assets of long listed products from Takeda to Teva Takeda Yakuhin, Takeda expects to record approximately 100 billion yen (~$885 million) of "gains on transfer of business" under "other operating income" in its fiscal year 2016 consolidated financials. The new business venture is expected to be accretive to Teva's non-generally accepted accounting principles (GAAP) earnings per share beginning in 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze